<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Cardiac <z:hpo ids='HP_0011034'>amyloidosis</z:hpo> of transthyretin fibril protein (ATTR) type is an infiltrative <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> characterised by ventricular wall thickening and diastolic <z:hpo ids='HP_0001635'>heart failure</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Increased access to cardiovascular magnetic resonance imaging has led to a marked increase in referrals to our centre of Caucasian patients with <z:mp ids='MP_0002169'>wild-type</z:mp> ATTR (senile systemic) <z:hpo ids='HP_0011034'>amyloidosis</z:hpo> and Afro-Caribbean patients with the hereditary ATTR V122I type </plain></SENT>
<SENT sid="2" pm="."><plain>Both subtypes present predominantly as isolated <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>The differential diagnosis includes cardiac amyloid light-chain (AL) <z:hpo ids='HP_0011034'>amyloidosis</z:hpo>, which has a poorer prognosis and can be amenable to chemotherapy </plain></SENT>
<SENT sid="4" pm="."><plain>We review here the clinical features of cardiac ATTR <z:hpo ids='HP_0011034'>amyloidosis</z:hpo> and describe the diagnostic tests to determine ATTR type </plain></SENT>
<SENT sid="5" pm="."><plain>Correct diagnosis is ever more crucial given that several novel therapies for ATTR <z:hpo ids='HP_0011034'>amyloidosis</z:hpo> are on the near horizon </plain></SENT>
</text></document>